Novavax Secures $300M Credit Facility

TL;DR

Novavax just landed a $300M loan to pay off old debt and fund operations.

AI Summary

On March 22, 2024, Novavax, Inc. entered into a Material Definitive Agreement, specifically a Credit Agreement with an initial aggregate principal amount of $300 million. This agreement involves a syndicate of lenders and is intended to refinance existing debt and provide working capital.

Why It Matters

This new credit facility provides Novavax with significant financial flexibility, potentially improving its ability to fund operations and strategic initiatives.

Risk Assessment

Risk Level: medium — While the credit facility provides capital, the company's ability to manage its debt obligations and operational performance remains a key factor.

Key Numbers

• $300M — Credit Facility Amount (Initial aggregate principal amount to refinance debt and provide working capital.)

Key Players & Entities

• Novavax, Inc. (company) — Registrant
• $300 million (dollar_amount) — Initial aggregate principal amount of the Credit Agreement
• March 22, 2024 (date) — Date of the Material Definitive Agreement

FAQ

Key Financial Figures

• $0.01 — registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Se
• $185 million — or SAR, the Company agreed to pay up to $185 million to Fujifilm in connection with cancella
• $68.6 m — m in 2023 under the Prior SAR, totaling $68.6 million, were subject to Fujifilm's oblig
• $42 million — ent, on March 25, 2024 the Company paid $42 million to Fujifilm, the parties agreed to a mu

Filing Documents

• tm249881d1_8k.htm (8-K) — 25KB
• 0001104659-24-039006.txt ( ) — 193KB
• nvax-20240322.xsd (EX-101.SCH) — 3KB
• nvax-20240322_lab.xml (EX-101.LAB) — 33KB
• nvax-20240322_pre.xml (EX-101.PRE) — 22KB
• tm249881d1_8k_htm.xml (XML) — 3KB

01

Item 1.01 Entry into a Material Definitive Agreement. On March 21, 2024, Novavax, Inc. (the "Company"), FUJIFILM Diosynth Biotechnologies UK Limited ("FDBK"), FUJIFILM Diosynth Biotechnologies Texas, LLC ("FDBT") and FUJIFILM Diosynth Biotechnologies USA, Inc. ("FDBU" and together with FDBK and FDBT, "Fujifilm") entered into a Confidential Settlement Agreement and Release (the "Settlement Agreement") to resolve disputes regarding amounts that Fujifilm claimed were due under a prior Confidential Settlement Agreement and Release effective September 30, 2022 (the "Prior SAR") by and between the Company and Fujifilm. Under the Prior SAR, the Company agreed to pay up to $185 million to Fujifilm in connection with cancellation of manufacturing activity at FDBT. The final two quarterly installments due to Fujifilm in 2023 under the Prior SAR, totaling $68.6 million, were subject to Fujifilm's obligation to use commercially reasonable efforts to mitigate losses associated with the vacant manufacturing capacity caused by the termination of manufacturing activities at FDBT. On October 2, 2023, the Company sent Fujifilm a notice of breach and refused to pay the final two installments based on its contention that Fujifilm had not used commercially reasonable efforts to mitigate losses and should have offset some portion of the final two payments. On October 30, 2023, Fujifilm filed a demand for arbitration with Judicial Arbitration and Mediation Services seeking payment of the full amount (the "Arbitration"). Pursuant to the Settlement Agreement, on March 25, 2024 the Company paid $42 million to Fujifilm, the parties agreed to a mutual release of claims arising from, under or otherwise in connection with the Prior SAR, and Fujifilm has agreed to dismiss the Arbitration. The foregoing description of the material terms of the Settlement Agreement does not purport to be complete and is qualified in its entirety by reference to the Settlement Agreement, which will be filed wi

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Novavax, Inc. Date: March 26, 2024 By: /s/ Mark J. Casey Name: Mark J. Casey Title: Executive Vice President, Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR